← Betta Pharmaceuticals overview

Betta Pharmaceuticals vs Sichuan Kelun-Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Betta Pharmaceuticals Co Ltd (300558.CS)

Q3 2026
▲4

Betta's lung cancer drug wins key approvals as profit doubles

  • Ensartinib adjuvant approval expands market China approved ensartinib for adjuvant treatment of ALK-positive lung cancer after surgery, making it only the second such drug globally. This opens a new patient group and should lift future sales, though the company warns actual uptake is uncertain.

    New regulatory approval directly expands the drug's addressable market and revenue potential.

  • Strong NEJM data backs ensartinib The ELEVATE study showed ensartinib cut the risk of lung cancer returning or death by 80% versus placebo. Publication in a top medical journal builds doctor confidence and supports the drug's use, helping drive prescriptions and sales.

    High-quality clinical evidence is a key driver of adoption and pricing power for a new drug.

  • Bevacizumab added to essential medicines list Bevacizumab joined China's National Essential Medicines List, which helps it reach more hospitals and primary care. This should boost sales volume, though the list can also bring price pressure over time.

    List inclusion is a direct demand driver for an existing product.

  • Interim profit more than doubles First-half net profit rose 116% to 302 million yuan on 14% higher revenue, with earnings per share up 118%. The strong profit growth shows the business is scaling and supports a higher share price, though cash flow slipped slightly.

    Profit growth is a core fundamental driver of stock valuation.

August 2026
▲4

Betta's lung cancer drug wins key approvals as profit doubles

  • Ensartinib adjuvant approval expands market China approved ensartinib for adjuvant treatment of ALK-positive lung cancer after surgery, making it only the second such drug globally. This opens a new patient group and should lift future sales, though the company warns actual uptake is uncertain.

    New regulatory approval directly expands the drug's addressable market and revenue potential.

  • Strong NEJM data backs ensartinib The ELEVATE study showed ensartinib cut the risk of lung cancer returning or death by 80% versus placebo. Publication in a top medical journal builds doctor confidence and supports the drug's use, helping drive prescriptions and sales.

    High-quality clinical evidence is a key driver of adoption and pricing power for a new drug.

  • Bevacizumab added to essential medicines list Bevacizumab joined China's National Essential Medicines List, which helps it reach more hospitals and primary care. This should boost sales volume, though the list can also bring price pressure over time.

    List inclusion is a direct demand driver for an existing product.

  • Interim profit more than doubles First-half net profit rose 116% to 302 million yuan on 14% higher revenue, with earnings per share up 118%. The strong profit growth shows the business is scaling and supports a higher share price, though cash flow slipped slightly.

    Profit growth is a core fundamental driver of stock valuation.

Latest
▲4

Betta's lung cancer drug wins key approvals as profit doubles

  • Ensartinib adjuvant approval expands market China approved ensartinib for adjuvant treatment of ALK-positive lung cancer after surgery, making it only the second such drug globally. This opens a new patient group and should lift future sales, though the company warns actual uptake is uncertain.

    New regulatory approval directly expands the drug's addressable market and revenue potential.

  • Strong NEJM data backs ensartinib The ELEVATE study showed ensartinib cut the risk of lung cancer returning or death by 80% versus placebo. Publication in a top medical journal builds doctor confidence and supports the drug's use, helping drive prescriptions and sales.

    High-quality clinical evidence is a key driver of adoption and pricing power for a new drug.

  • Bevacizumab added to essential medicines list Bevacizumab joined China's National Essential Medicines List, which helps it reach more hospitals and primary care. This should boost sales volume, though the list can also bring price pressure over time.

    List inclusion is a direct demand driver for an existing product.

  • Interim profit more than doubles First-half net profit rose 116% to 302 million yuan on 14% higher revenue, with earnings per share up 118%. The strong profit growth shows the business is scaling and supports a higher share price, though cash flow slipped slightly.

    Profit growth is a core fundamental driver of stock valuation.

Sichuan Kelun-Biotech (6990.HK)

Q3 2026
▲4▼1

Kelun-Biotech's pipeline and sales advance, but bribery probe clouds the story

  • Lung-cancer combo succeeds in Phase III The sac-TMT plus pembrolizumab combo met its main goal in first-line PD-L1-negative non-squamous lung cancer — the first ADC-plus-immunotherapy Phase III win in this group. Success lifts hopes for a big new use of its flagship drug, supporting the stock.

    A major clinical win for the core drug is a key force behind the shares.

  • New dual-payload ADC enters clinic China's drug regulator cleared SKB565, the company's first dual-payload ADC, for human testing in advanced solid tumors. It is early-stage, but shows the pipeline keeps producing new candidates, which supports long-term growth expectations.

    Pipeline progress is a core driver of biotech valuation.

  • Bribery allegations create legal and reputational risk A whistleblower letter alleges commercial bribery tied to the company's flagship drug sac-TMT, naming hospitals in Beijing. Kelun-Biotech denies it and threatens legal action. If proven, fines or sales restrictions could hurt; even unproven, it dents trust.

    This is the main counterweight and a real risk to the stock.

  • Interim sales jump 112%, cash raised First-half product sales rose 112% to RMB 657 million, helped by insurance coverage for three sac-TMT uses and a new breast-cancer approval. The company also raised HK$2.72 billion in a share placing and dropped its 'B' marker, easing funding worries.

    Strong commercial execution and fresh capital directly support the shares.

  • Partner's asthma drug moves to Phase III Partner Windward Bio reported positive Phase 2 asthma results for SKB378/WIN378, showing lasting lung-function gains with twice-yearly dosing, and started Phase 3. Success could bring milestone payments and royalties, adding a new growth path beyond cancer.

    Partner validation of another pipeline asset is a fresh positive catalyst.

August 2026
▲4▼1

Kelun-Biotech's pipeline and sales advance, but bribery probe clouds the story

  • Lung-cancer combo succeeds in Phase III The sac-TMT plus pembrolizumab combo met its main goal in first-line PD-L1-negative non-squamous lung cancer — the first ADC-plus-immunotherapy Phase III win in this group. Success lifts hopes for a big new use of its flagship drug, supporting the stock.

    A major clinical win for the core drug is a key force behind the shares.

  • New dual-payload ADC enters clinic China's drug regulator cleared SKB565, the company's first dual-payload ADC, for human testing in advanced solid tumors. It is early-stage, but shows the pipeline keeps producing new candidates, which supports long-term growth expectations.

    Pipeline progress is a core driver of biotech valuation.

  • Bribery allegations create legal and reputational risk A whistleblower letter alleges commercial bribery tied to the company's flagship drug sac-TMT, naming hospitals in Beijing. Kelun-Biotech denies it and threatens legal action. If proven, fines or sales restrictions could hurt; even unproven, it dents trust.

    This is the main counterweight and a real risk to the stock.

  • Interim sales jump 112%, cash raised First-half product sales rose 112% to RMB 657 million, helped by insurance coverage for three sac-TMT uses and a new breast-cancer approval. The company also raised HK$2.72 billion in a share placing and dropped its 'B' marker, easing funding worries.

    Strong commercial execution and fresh capital directly support the shares.

  • Partner's asthma drug moves to Phase III Partner Windward Bio reported positive Phase 2 asthma results for SKB378/WIN378, showing lasting lung-function gains with twice-yearly dosing, and started Phase 3. Success could bring milestone payments and royalties, adding a new growth path beyond cancer.

    Partner validation of another pipeline asset is a fresh positive catalyst.

Latest
▲4▼1

Kelun-Biotech's pipeline and sales advance, but bribery probe clouds the story

  • Lung-cancer combo succeeds in Phase III The sac-TMT plus pembrolizumab combo met its main goal in first-line PD-L1-negative non-squamous lung cancer — the first ADC-plus-immunotherapy Phase III win in this group. Success lifts hopes for a big new use of its flagship drug, supporting the stock.

    A major clinical win for the core drug is a key force behind the shares.

  • New dual-payload ADC enters clinic China's drug regulator cleared SKB565, the company's first dual-payload ADC, for human testing in advanced solid tumors. It is early-stage, but shows the pipeline keeps producing new candidates, which supports long-term growth expectations.

    Pipeline progress is a core driver of biotech valuation.

  • Bribery allegations create legal and reputational risk A whistleblower letter alleges commercial bribery tied to the company's flagship drug sac-TMT, naming hospitals in Beijing. Kelun-Biotech denies it and threatens legal action. If proven, fines or sales restrictions could hurt; even unproven, it dents trust.

    This is the main counterweight and a real risk to the stock.

  • Interim sales jump 112%, cash raised First-half product sales rose 112% to RMB 657 million, helped by insurance coverage for three sac-TMT uses and a new breast-cancer approval. The company also raised HK$2.72 billion in a share placing and dropped its 'B' marker, easing funding worries.

    Strong commercial execution and fresh capital directly support the shares.

  • Partner's asthma drug moves to Phase III Partner Windward Bio reported positive Phase 2 asthma results for SKB378/WIN378, showing lasting lung-function gains with twice-yearly dosing, and started Phase 3. Success could bring milestone payments and royalties, adding a new growth path beyond cancer.

    Partner validation of another pipeline asset is a fresh positive catalyst.